SMSaikat Mandal

Saikat Mandal

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article

Previous Organizations / Institutes

The organizations / institutes from the scholar's other articles in the past ten years


Saikat Mandal has a total of 58 co-authors. Here are the top co-authors by number of shared publications:


Latest Publications

  • Open Access

    Inhibitory proteins of Bacillus subtilis interact within the membrane to block intramembrane protease activity

    by Saikat Mandal, Alanah Soriano, Caroline Erpelding, Jackson Ruffner, Eric Smith, Benjamin J. Orlando, Lee Kroos

    Intramembrane proteases (IPs) are crucial for diverse signaling pathways, including some that regulate the virulence of pathogenic bacteria. A better understanding of mechanisms controlling IP activity is necessary to guide therapeutic development. Bacillus subtilis SpoIVFB is an IP with two natural inhibitory proteins, BofA and SpoIVFA. These proteins form a complex with SpoIVFB and prevent it from cleaving Pro-σ K during endosporulation. We investigated proximity between BofA and SpoIVFA in the SpoIVFB inhibition complex using in vivo disulfide crosslinking in Escherichia coli . We discovered that two parts of the BofA C-terminal region are proximal to the SpoIVFA transmembrane segment (TMS). Our results support predictions that the BofA C-terminal region adopts an unusual structure within the membrane and interacts with the SpoIVFA TMS to block SpoIVFB cleavage of Pro-σ K . Endospore-forming Bacilli , including several pathogenic species, encode BofA and SpoIVFA orthologs, which likely interact in a similar fashion to inhibit their SpoIVFB ortholog. It may be possible to control SpoIVFB activity and hence endosporulation with modulators that target the interaction between BofA and SpoIVFA. IMPORTANCE: Regulated intramembrane proteolysis (RIP) pathways govern important processes in all three domains of life. A key component of RIP pathways is an intramembrane protease (IP), which cleaves one or more substrates within a membrane. Developing modulators of IPs has been challenging, particularly for metallo-IPs. Bacterial metallo-IPs function in RIP pathways that control the virulence of many pathogens. SpoIVFB is a metallo-IP necessary for endosporulation of Bacillus subtilis . Endosporulation enhances the survival of pathogenic Bacilli , which encode orthologs of SpoIVFB and its natural inhibitory proteins BofA and SpoIVFA. Here, we present the first experimental evidence for contacts between BofA and SpoIVFA within the membrane-embedded SpoIVFB inhibition complex, providing foundations for a deeper understanding of mechanisms controlling metallo-IP activity.

  • Open Access

    Substrate engagement by the intramembrane metalloprotease SpoIVFB

    by Melanie A. Orlando, Hunter J. T. Pouillon, Saikat Mandal, Lee Kroos, Benjamin J. Orlando

    S2P intramembrane metalloproteases regulate diverse signaling pathways across all three domains of life. However, the mechanism by which S2P metalloproteases engage substrates and catalyze peptide hydrolysis within lipid membranes has remained elusive. Here we determine the cryo-EM structure of the S2P family intramembrane metalloprotease SpoIVFB from Bacillus subtilis bound to its native substrate Pro-σK. The structure and accompanying biochemical data demonstrate that SpoIVFB positions Pro-σK at the enzyme active site through a β-sheet augmentation mechanism, and reveal key interactions between Pro-σK and the interdomain linker connecting SpoIVFB transmembrane and CBS domains. The cryo-EM structure and molecular dynamics simulation reveal a plausible path for water to access the membrane-buried active site of SpoIVFB, and suggest a possible role of membrane lipids in facilitating substrate capture. These results provide key insight into how S2P intramembrane metalloproteases capture and position substrates for hydrolytic proteolysis within the hydrophobic interior of a lipid membrane.


  • Anticancer Behavior of Pyrrolidine-Based Palladium(II) Complexes and Biophysical Approach on Their DNA, BSA Binding Activity, Molecular Docking, and DFT Study

    by Swarup Kumar Tarai, Angana Pan, Pritam Biswas, Rituparna Bhaduri, Saikat Mandal, Animesh Paul, Sujoy Baitalik, Ashish Bhattacharjee, Sankar Ch. Moi

    A series of pyrrolidine-based Pd(II) complexes, [Pd(AEP)Cl-2] (C-1), [Pd(AEP)(OH2)(2)](2+)(C-2), [Pd(AEP)(L-cys)](+) (C-3), [Pd(AEP)(N-ac-L-cys)](C-4), [Pd(AEP)(GSH)] (C-5), and [Pd(AEP)(DL-meth)](2+) (C-6)(where, AEP = 1-(2-aminoethyl)pyrrolidine, L-cys = l-cysteine,N-ac-L-cys = N-acetyl-l-cysteine, GSH =glutathione, and DL-meth = dl-methionine), as anticancerdrug candidates have been synthesized and characterized. The DNA bindingproperty of the complexes was executed by gel electrophoresis andspectrophotometric and viscometric methods, and their interactionwith BSA was also investigated by various spectroscopic methodologies.The binding activity of the Pd(II) complexes with DNA and BSA wereassessed to evaluate their binding mode and binding constants. Moleculardocking was performed to correlate with the experimental results onthe interaction of the complexes with DNA and BSA. The changes inthe microenvironmental and structural properties of BSA are monitoredby a synchronous and 3D fluorescence study. The structural propertieswere evaluated by DFT and TD-DFT studies. The anticarcinogenic activityof the Pd(II) complexes was assessed by PASS prediction software tocorroborate with the experimental results of the anticancer activityof the complexes. The ROS generation in cancer cell lines has beeninvestigated, and the cell death mechanism through apoptosis was confirmedby measuring the protein expression. All these complexes have excellentanticancer activity compared to ancillary ligands. The cancer cellline (HCT116) shows almost similar or better cell inhibition activitywhen treated with the Pd(II) complexes compared to cisplatin, whereasthe adverse effect is minimum on a normal cell (NKE). Both the Pd(II)and Pt(II) complexes carrying the same ligands reveal almost similarantiproliferative activity.


  • Biophysical study on DNA and BSA binding activity of Cu(II) complex: Synthesis, molecular docking, cytotoxic activity, and theoretical approach

    by Swarup Kumar Tarai, Saikat Mandal, Arup Tarai, Ipsita Som, Angana Pan, Arka Bagchi, Arunima Biswas, Sankar Ch. Moi

    The bidentate (N, O) donor Schiff base, methyl‐4‐(2‐hydroxybenzylidene‐amino) benzoate (HL), was synthesized for the synthesis of CuL2 complex. Their structures were characterized by single crystal X‐ray diffraction and spectroscopic methods. The important structural features of ligand HL are (space group: Pca21; a = 6.1434(7) Å; b = 7.1021(7) Å; c = 28.963(3) Å; α = 90.00°; β = 90.00°, and γ = 90.00°) and of CuL2 are (space group: P21/n; a = 15.763(7) Å; b = 8.1921(5) Å, and c = 20.1955(8) Å; α = 90.00°; β = 96.547(4)°, and γ = 90.00°). The DFT/TD‐DFT studies were performed to evaluate the structure optimization, MEP plot, and electronic spectroscopy data as well as the HOMO‐LUMO energy and also other electronic descriptor properties. The DNA and BSA binding property of both the ligand and complex were studied employing a variety of spectroscopic methods, viscosity experiments, and gel electrophoresis technique. Their biophysical study including 3D fluorescence, FRET calculation, and anisotropy measurements with BSA were studied by spectrofluorometric methods. The molecular docking simulation of the ligand HL and CuL2 was executed with DNA and BSA to observe their different weak and strong binding interactions and to compare their binding aptitude with biomolecules and experimental results. The software “PASS” for drug likeness prediction and “ADMET” for bioactivity were implemented to get an idea about the antineoplastic and bioactivity aspects of HL and CuL2 complex. The anticancer property of the Cu(II) complex was measured by MTT assay against human breast carcinomas (MCF‐7) cancer cell line and as well as normal human embryonic kidney cells (HEK293) and is less toxic and comparable anticancer activity compared to cisplatin and oxaliplatin. The annexin V‐FITC, propidium iodide assay by flow cytometric method, and reactive oxygen species (ROS) production assay by DCFDA were assessed in presence of the HL and CuL2 for their cell death mechanism proceed via either apoptosis or necrosis.


  • Cytotoxic behavior and DNA/BSA binding activity of thiosemicarbazone based Ni(II) complex: bio-physical, molecular docking and DFT study

    by Swarup Kumar Tarai, Arup Tarai, Saikat Mandal, Bhaskar Nath, Ipsita Som, Rituparna Bhaduri, Arka Bagchi, Solanki Sarkar, Arunima Biswas, Sankar Ch. Moi


  • Open Access

    Host–Guest Encapsulation of RIBO with TSC4X: Synthesis, Characterization, and Its Application by Physicochemical and Computational Investigations

    by Biswajit Ghosh, Niloy Roy, Saikat Mandal, Salim Ali, Pranish Bomzan, Debadrita Roy, Salman Haydar, Vikas Kumar Dakua, Anupam Upadhyay, Debabrata Biswas, et al.

    In our present work, we synthesized a new encapsulated complex denoted as RIBO-TSC4X, which was derived from an important vitamin riboflavin (RIBO) and p-sulfonatothiacalix[4]arene(TSC4X). The synthesized complex RIBO-TSC4X was then characterized by utilizing several spectroscopic techniques such as 1H-NMR, FT-IR, PXRD, SEM, and TGA. Job's plot has been employed to show the encapsulation of RIBO (guest) with TSC4X (host) having a 1:1 molar ratio. The molecular association constant of the complex entity (RIBO-TSC4X) was found to be 3116.29 ± 0.17 M-1, suggesting the formation of a stable complex. The augment in aqueous solubility of the RIBO-TSC4X complex compared to pure RIBO was investigated by UV-vis spectroscopy, and it was viewed that the newly synthesized complex has almost 30 times enhanced solubility over pure RIBO. The enhancement of thermal stability upto 440 °C for the RIBO-TSC4X complex was examined by TG analysis. This research also forecasts RIBO's release behavior in the presence of CT-DNA, and at the same time, BSA binding study was also carried out. The synthesized RIBO-TSC4X complex exhibited comparatively better free radical scavenging activity, thereby minimizing oxidative injury of the cell as evident from a series of antioxidant and anti-lipid peroxidation assay. Furthermore, the RIBO-TSC4X complex showed peroxidase-like biomimetic activity, which is very useful for several enzyme catalyst reactions.


  • Brief Research on the Biophysical Study and Anticancer Behavior of Pt(II) Complexes: Their DNA/BSA Binding, Molecular Docking, and Cytotoxic Property

    by Saikat Mandal, Swarup Kumar Tarai, Priya Patra, Payel Nandi, Shukdeb Sing, Bijoy Rajak, Sankar Chandra Moi

    The potent bidentate carrier ligand 2-picolylamine (pic) has been used to synthesize Pt(II) complexes to know their bioactivity and anticancer property as reflected by PASS prediction software. The dichloro Pt(II) complex [Pt(pic)Cl2], Pt-1, and its hydrolyzed diaqua complex [Pt(pic)(OH2)2]2+, Pt-2, were synthesized. The thiol-containing Pt(II) complexes [Pt(pic)(l-cys)]+, Pt-3, and [Pt(pic)(L-ac-l-cy)]+, Pt-4, were synthesized from Pt-2, which was obtained from hydrolysis of Pt-1. Their biomolecular interactions with BSA and DNA were executed by spectroscopic methods, and their cytototoxic property was tested by the MTT assay. In vitro biomolecular interactions of Pt(II) complexes with BSA and DNA were investigated by different spectroscopic and viscosity measurement methods for their pharmacokinetic and pharmacodynamic importance. The conformational change of BSA in the presence of a drug candidate was studied by Förster resonance energy transfer calculation and synchronous and three-dimensional fluorescence spectroscopic studies. A theoretical approach on optimization structures, highest occupied molecular orbital-lowest unoccupied molecular orbital energy, global reactivity parameters, time-dependent density functional theory, and molecular docking with BSA and DNA was executed to strengthen and support the experimental observations. In vitro cytotoxic profiles of the complexes like the anticancer activity and their level of reactive oxygen species production were brought under consideration on A549 cancer cells and the normal human embryonic kidney cell line HEK-293. The cytotoxic property was compared with that of the recognized anticancer drug cisplatin.


  • Anticancer property and normal cell toxicity profile of pyrrolidine‐based platinum (II) complexes: Their DNA, BSA interaction, and molecular docking

    by Swarup Kumar Tarai, Angana Pan, Sriparna Das, Rituparna Bhaduri, Saikat Mandal, Sudipta Maitra, Sankar Chandra Moi

    The bioactivity and cytotoxic property of cis‐[Pt (AEP)Cl2] (C‐1); [Pt (AEP)(OH2)2](NO3)2 (C‐2); [Pt (AEP)(GSH) (C‐3)]; and [Pt (AEP)(DL‐meth)]2+(C‐4) (where AEP = 1‐[2‐Aminoethyl] pyrrolidine; GSH = Glutathione; DL‐meth = DL‐methionine) were extensively investigated to find out the more active and less toxic anticancer lead molecules. Spectroscopically characterized Pt (II) complexes (C‐1 to C‐4) were under investigation for their anticancer activity and bio‐molecular interaction with DNA and BSA. The binding property of the complexes toward DNA and BSA were evaluated by UV–Vis, fluorescence spectroscopy, gel electrophoresis, cyclic voltammetry (CV), circular dichroism (CD), and viscometric methods for their pharmacokinetic and pharmacodynamics importance. The BSA binding activity as well as their “Drug reservoir” property of Pt (II) complexes were highlighted for their biological significance. Furthermore, to assess the manner of interaction and also binding strength of the complexes with DNA and BSA molecule, a theoretical approach by molecular docking was performed, utilizing the optimized structure of the complexes. Structural optimization has been performed with density functional theory (DFT) correlation functional (B3LYP) at 6‐31G + (d, p) and LANL2DZ basis set was used for C, N, H, O, S, and metal, respectively. In vitro anticancer activity and level of ROS generation in presence of each complex were explored on A549 cancer cell as well as normal human cell lines HEK293, and their potential cytotoxic property was observed as compared to well‐known recognized anticancer cisplatin.